Search

Corcept Therapeutics Inc

Gesloten

SectorGezondheidszorg

113.13 3.19

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

108.28

Max

116.61

Belangrijke statistieken

By Trading Economics

Inkomsten

75M

43M

Verkoop

91M

256M

K/W

Sectorgemiddelde

248.445

56.432

EPS

0.36

Winstmarge

16.782

Werknemers

730

EBITDA

91M

47M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+23.95% upside

Dividenden

By Acuity

Volgende Winsten

3 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.3B

12B

Vorige openingsprijs

109.94

Vorige sluitingsprijs

113.13

Nieuwssentiment

By Acuity

13%

87%

8 / 339 Rangschikking in Healthcare

Corcept Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 sep 2026, 20:06 UTC

Corcept Therapeutics Inc is advancing, maintaining significant gains since Friday's close, despite earlier pulling back from a session high.

18 sep 2026, 20:02 UTC

Social Media
News

Shares of Corcept Therapeutics fell sharply despite a positive CHMP opinion on relacorilant for ovarian cancer and a reiterated Buy rating from HC Wainwright.

17 sep 2026, 20:01 UTC

News

Corcept Therapeutics shares are rising, supported by record revenue and net income growth for Q2 2026, along with an increased revenue guidance of up to $1.2 billion.

15 sep 2026, 20:07 UTC

Corcept Therapeutics Inc is trading lower amid a broader market decline, influenced by a significant drop in the NY Empire State Manufacturing Index.

14 sep 2026, 20:02 UTC

Corcept Therapeutics Inc shares are lower today amid broader market concerns over rising crude oil prices and inflation ahead of the Federal Reserve's interest rate decision.

11 sep 2026, 20:08 UTC

Corcept Therapeutics Inc shares are lower today, reflecting broader market trends amid volatility and recent inflation data showing a monthly increase of 0.4%.

10 sep 2026, 19:21 UTC

Corcept Therapeutics Inc shares are lower amid broader market declines and rising Treasury yields, with no specific company news identified.

8 sep 2026, 20:07 UTC

Corcept Therapeutics Inc shares are higher today, recovering from an early decline. The stock peaked midday but remains below the 20-day moving average.

2 sep 2026, 20:08 UTC

Corcept Therapeutics Inc. shares are lower today, breaking a recent trend of gains. The broader market is impacted by a weak ADP employment report.

1 sep 2026, 20:08 UTC

Corcept Therapeutics Inc shares are lower amid broader market declines driven by rising oil prices and increasing inflation concerns ahead of the Federal Reserve meeting.

28 aug 2026, 20:01 UTC

Corcept Therapeutics Inc shares are lower, continuing a four-day decline amid notable volatility and unusually high market volume. No specific news was identified.

27 aug 2026, 23:42 UTC

Corcept Therapeutics Inc is higher in after-market trading, recovering from earlier lows. Economic data showing a decline in jobless claims may support market sentiment.

26 aug 2026, 19:51 UTC

Corcept Therapeutics Inc shares are lower today, reaching a session low and marking a decline since Tuesday's close, with high trading volume noted.

25 aug 2026, 23:06 UTC

Corcept Therapeutics Inc shares are lower in after-market hours, reflecting a decline since Tuesday's close amid falling crude oil prices and easing geopolitical concerns.

24 aug 2026, 19:36 UTC

News

Corcept Therapeutics shares are lower despite Zacks raising Q3 2026 EPS estimate to $0.34. The company reported Q2 earnings of $0.36 per share.

21 aug 2026, 20:01 UTC

News

Corcept Therapeutics Inc is higher today, supported by strong sector performance and increased trading volume amid a positive growth outlook and upcoming FDA decision on Relacorilant.

20 aug 2026, 23:41 UTC

Corcept Therapeutics Inc. shares are trading roughly flat in after-market hours. The asset remains above its 20-day moving average.

13 aug 2026, 19:46 UTC

Corcept Therapeutics Inc is declining today, with no specific news identified. The stock peaked earlier but has since retraced from that high.

12 aug 2026, 19:16 UTC

Corcept Therapeutics Inc shares are higher today amid a positive trend in U.S. stocks, despite geopolitical tensions and rising crude oil prices.

11 aug 2026, 20:06 UTC

Corcept Therapeutics Inc. shares are lower today, having declined steadily after reaching a session high earlier. The stock remains above its 20-day moving average.

10 aug 2026, 19:16 UTC

Corcept Therapeutics Inc shares are higher today, recovering from an early drop despite a broader market decline amid labor market concerns.

7 aug 2026, 21:01 UTC

Corcept Therapeutics Inc shares are lower in after-market trading, declining despite being above its 20-day moving average and near the upper end of its one-month range.

5 aug 2026, 19:56 UTC

Corcept Therapeutics Inc's shares are higher today, reflecting a generally positive market environment. The stock remains significantly above its 20-day moving average.

4 aug 2026, 19:16 UTC

Corcept Therapeutics Inc shares are lower today, continuing a decline seen over the past three trading days. No specific news was identified for the drop.

3 aug 2026, 20:02 UTC

Corcept Therapeutics Inc shares are lower today amid a decline in the Pharmaceuticals sub-sector, with unusually high trading volume noted.

31 jul 2026, 22:26 UTC

Corcept Therapeutics shares are higher in after-market hours, peaking shortly after Friday's close despite no specific news to explain the movement.

30 jul 2026, 23:11 UTC

Corcept Therapeutics shares traded lower in after-market hours, reflecting broader market uncertainty following the Federal Reserve's interest rate decision.

29 jul 2026, 23:41 UTC

Social Media
News

Corcept Therapeutics shares are trading higher in after-market hours following strong second-quarter results, with revenue of $256.1 million and raised full-year guidance.

28 jul 2026, 19:46 UTC

News

Corcept Therapeutics shares are higher ahead of Q2 earnings tomorrow, with analysts expecting revenue growth to slow to 8.4% year-on-year.

27 jul 2026, 23:46 UTC

Shares of Corcept Therapeutics Inc declined in after-hours trading, dipping to a low shortly after the market reopened. No specific news was identified.

Peer Vergelijking

Prijswijziging

Corcept Therapeutics Inc Prognose

Koersdoel

By TipRanks

23.95% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 141 USD  23.95%

Hoogste 165 USD

Laagste 50 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corcept Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

4

Buy

0

Hold

1

Sell

Sentiment

By Acuity

8 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.